Cisapride (Propulsid)

A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)

Also Known As:

Networked: 696 relevant articles (139 outcomes, 167 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Augood, C: 4 articles (01/2003 - 01/2000)
2.	Logan, S: 4 articles (01/2003 - 01/2000)
3.	MacLennan, S: 4 articles (01/2003 - 01/2000)
4.	Sakamoto, Kengo: 3 articles (08/2021 - 01/2005)
5.	Sugiyama, Atsushi: 3 articles (08/2021 - 06/2003)
6.	Itoh, Zen: 3 articles (07/2008 - 08/2007)
7.	Omura, Satoshi: 3 articles (07/2008 - 08/2007)
8.	Takanashi, Hisanori: 3 articles (07/2008 - 08/2007)
9.	Gilbert, R: 3 articles (01/2003 - 01/2000)
10.	Talley, N J: 3 articles (09/2002 - 03/2001)

Related Diseases

1.	Dyspepsia (Indigestion) 05/01/1994 - "At the end of cisapride treatment, the most frequently reported symptoms of functional dyspepsia were significantly improved. " 04/01/1995 - "We were unable to show major differences in the short-term efficacy of cisapride and placebo in functional dyspepsia. " 01/01/1993 - "A double-blind, placebo-controlled trial was performed to determine the therapeutic efficacy of cisapride in patients with refractory functional dyspepsia. " 01/01/1989 - "Chronic idiopathic dyspepsia Cisapride has been shown to be effective in both improving symptoms and also delayed gastric emptying in a six week study. " 06/01/1995 - "Cisapride is also effective in improving symptoms in patients with functional dyspepsia. "
2.	Gastroesophageal Reflux (GERD) 09/01/1997 - "In the acute management of GERD, cisapride is superior to placebo and has the same efficacy as H2 receptor antagonists (H2RAs) in several clinical trials. " 03/01/2017 - "The prokinetic agent cisapride is effective for the treatment of gastroesophageal reflux disease (GERD) in infants and children, but is no longer used for this purpose because of safety concerns. " 08/01/1998 - "Cisapride, a prokinetic agent, has been reported effective for treating mild-to-moderate grade gastroesophageal reflux disease. " 06/01/1998 - "Cisapride is a prokinetic agent that facilitates gastrointestinal motility and is widely used for the treatment of gastroesophageal reflux disease (GERD) in adults and children. " 01/01/1991 - "These results suggest that in addition to other therapeutic measurements, such as positional treatment (which was previously demonstrated to be effective in this age group), cisapride might be of benefit in the treatment of gastroesophageal reflux disease."
3.	Gastroparesis 05/01/1991 - "We conclude that during a 12-month open trial, cisapride was effective in improving gastric emptying in patients with gastric stasis and consistently improved symptoms in those with gastroparesis." 01/01/1989 - "Diabetic gastroparesis In a four week study, cisapride has been shown to be effective in improving symptoms and solid phase gastric emptying. " 04/10/1995 - "The gastrointestinal prokinetic drug, cisapride, is widely used for the treatment of diabetic gastroparesis and disorders of gastrointestinal motility. " 01/01/1994 - "However, the efficacy of cisapride in end-stage gastroparesis remains less clear. " 02/01/1993 - "There is little information about the effects of cisapride on human antropyloroduodenal motility, despite its documented efficacy for increasing the rate of gastric emptying in patients with gastroparesis. "
4.	Constipation 01/01/1996 - "To establish whether cisapride is beneficial in children with intractable constipation, an open trial was performed. " 08/01/2002 - "We conclude that cisapride is effective in the treatment of constipation in patients with PSS." 01/01/2000 - "Cisapride was effective in the treatment of children with constipation." 01/01/2000 - "To determine whether cisapride is effective in the treatment of children with constipation. " 01/01/1994 - "We conclude that cisapride is effective in the treatment of constipation in idiopathic PD."
5.	Ulcer 01/01/1996 - "The role of gastric mucosal sulphydryls in the ulcer-protecting effects of cisapride." 08/01/1993 - "This finding was confirmed using lifetable analysis, with a 35% reduction (95% confidence intervals 10-59%, p < 0.05) in the proportion of ulcer relapses in patients who had received cisapride compared with those treated with placebo. " 08/01/1993 - "The 12 month crude relapse rates (that underestimate the probability of ulcer recurrence) showed that cisapride was superior to placebo (34% (11/32) relapsed on cisapride v 68% (23/34) on placebo, p = 0.007). " 06/01/1991 - "Controlled studies showed that cisapride is effective in non-ulcer dyspepsia. " 05/01/2005 - "Lack of effect of Helicobacter pylori on symptom improvement with a prokinetic medication, cisapride, in patients with non-ulcer dyspepsia."

Related Drugs and Biologics

1.	Domperidone (Domperidon)
2.	Metoclopramide (Reglan)
3.	Ranitidine (Zantac)
4.	Omeprazole (Prilosec)
5.	Acids
6.	Cimetidine (Biomet)
7.	Antral
8.	tegaserod (Zelnorm)
9.	Neostigmine (Neostigmine Bromide)
10.	Cholinergic Antagonists (Anticholinergics)

Related Therapies and Procedures

1.	Therapeutics
2.	Enteral Nutrition (Feeding, Tube)
3.	Lithotripsy (Extracorporeal Shockwave Lithotripsy)
4.	Oral Administration
5.	Glycemic Control